Rapid 3-D Delineation of Cell Nuclei for High-Content Screening Platforms [Diagnostic/Imaging]

Tech ID: ger000864



This invention addresses the problem of segmentation of nuclei and quantification of respective nuclear signals in digitized preparations of human specimens imaged in three dimensions (3-D). The software is based on a new method to delineate nuclei by means of 3-D radial symmetries and has been tested on high-resolution image data of human cancer cells treated by drugs. This can become a useful tool for drug screening that utilizes imaging to investigate macro and microscopic changes induced by drugs in single cells.


Technology Description 

• The nuclei detection performance of the new method, 3D-RSD, was evaluated by means of manually generated ground truth from 2351 nuclei (27 confocal stacks).

• The method was validated with very good overall segmentation performance compared to two state-of-the-art nuclei segmentation methods. It also offers good processing speed and is less sensitive to staining patterns.



High-content screening (HCS) platform vendors often produce image analysis software but limitations of cell confluency, complexity of nuclear staining as well as poor contrast can result in unreliable 3-D image processing. The software described in this invention provides more reliable image analysis. Furthermore, the existing commercial software products are often specific to the platform. This invention can provide a standardized single analysis platform where a lab or facility has multiple instruments.



• The algorithm could be built into an existing drug screening platform utilizing images from a confocal microscope.

• Faster and more reliable screening can reduce cost and increase efficiency for drug screening and development. Morphological changes in single cells can indicate effects of drug action.


Intellectual Property




Gertych et al. Rapid 3-D delineation of cell nuclei for high-content screening platforms. Comput Biol Med. 2015, pii: S0010-4825(15)00143-2. [LINK]


Patent Information:
For Information, Contact:
Wenyue Du
Senior Associate - IP Management & Licensing
Arkadiusz Gertych
Beatrice Knudsen
Drug Discovery/Screening